Idorsia publishes a Financial Status required for an upcoming bondholder
meeting
Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of
March 31, 2024, required for an upcoming bondholder meeting, now available on
the company website Bondholder meeting now planned for early May as the company
continues to engage with bondholders
Allschwil, Switzerland – April 17, 2024
Idorsia Ltd (SIX: IDIA) today announced that its Unaudited Financial Status as
of March 31, 2024, required for an upcoming bondholder meeting is available on
the company website at the following link:
http://www.idorsia.com/investors/financial-information
Idorsia continues to engage with bondholders on options and terms regarding
the repayment of the convertible bond maturing on July 17, 2024 (ISIN:
CH0426820350). As a result, the bondholder meeting initially contemplated for
April 30, 2024, is expected to take place shortly thereafter.
André C. Muller, Chief Financial Officer, commented:
“We have had many interactions with our bondholders in the past week. We are
finalizing our proposed amendment to the terms and conditions of the bond,
taking into account the bondholder needs as well as our objective to avoid
unnecessary dilution. We expect to publish the invitation to the bondholders
meeting in the next few days.”
Notes to the editor
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more
opportunities and we want to help more patients. In order to achieve this, we
will develop Idorsia into a leading biopharmaceutical company, with a strong
scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is
specialized in the discovery, development and commercialization of small
molecules to transform the horizon of therapeutic options. Idorsia has a
25-year heritage of drug discovery, a broad portfolio of innovative drugs in
the pipeline, an experienced team of professionals covering all disciplines
from bench to bedside, and commercial operations in Europe and North America –
the ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June
2017 and has over 750 highly qualified specialists dedicated to realizing our
ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain 'forward-looking statements', relating
to the company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects', 'may',
'are expected to', 'will', 'will continue', 'should', 'would be', 'seeks',
'pending' or 'anticipates' or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions of the
company's investment and research and development programs and anticipated
expenditures in connection therewith, descriptions of new products expected to
be introduced by the company and anticipated customer demand for such products
and products in the company's existing portfolio. Such statements reflect the
current views of the company with respect to future events and are subject to
certain risks, uncertainties and assumptions. Many factors could cause the
actual results, performance or achievements of the company to be materially
different from any future results, performances or achievements that may be
expressed or implied by such forward-looking statements. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those described herein
as anticipated, believed, estimated or expected.
Anhang Medienmitteilung PDF